Skip to main content
Midas Edge

Glucotrack Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

GCTK$1.39-32.2%Stored close · as of Oct 29, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(in thousands of US Dollars except share data) (unaudited)

In thousands of US Dollars (except share data)
Common Stock · Additional · Receipts · Accumulated Other · Total Stockholders’
Numbers of Shares · Amount · Paid-in Capital · on account of shares · Comprehensive Income · Accumulated Deficit · Equity (Deficit)
Balance as of January 1, 20233,099,982$3$103,107$4$17$(101,901)$1,230
Loss for the period-----(4,685)(4,685)
Other comprehensive income----17-17
Stock-based compensation--260--260
Deemed dividend resulted from trigger of down round protection feature of certain warrants granted--855--(855)-
Issuance of Common Stock and pre-funded warrants upon completion of public offering, net of offering expenses1,075,29418,729---8,730
Issuance of restricted shares as compensation towards directors2,998-(*)9(4)--5
Balance as of September 30, 20234,178,274$4$112,960$-$34$(107,441)$5,557
Balance at July 1, 20234,178,274$4$112,929$-$28$(105,218)$7,743
Loss for the period-----(2,223)(2,223)
Other comprehensive income----6-6
Stock-based compensation--31---31
Balance as of September 30, 20234,178,274$4$112,960$-$34$(107,441)$5,557
Balance as of January 1, 20244,178,274$4$112,982$48$16$(109,853)$3,197
Loss for the period-----(12,503)(12,503)
Other comprehensive income----(11)-(11)
Stock-based compensation--239---239
Issuance of restricted shares as compensation towards directors86,861(*)126(48)--78
Restricted shares to be issued as compensation towards directors---100--100
Exercise of prefunded warrants into shares (Note 3A)395,294(*)-----
Exchange of warrants into shares (Note 3B)718,6411(1)----
Issuance of Common Stock upon private placement transaction (Note 3D)79,366(*)500---500
Issuance of detachable warrants through private placement transactions (Note 3F and Note 3H)--2,635---2,635
Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J)293,59011,742---1,743
Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B)20,000------
Balance as of September 30, 20245,772,026$6$118,223$100$5$(122,356)$(4,022)
Balance as of July 1, 20245,478,436$5$113,903$50$22$(117,269)$(3,289)
Loss for the period-----(5,087)(5,087)
Other comprehensive income----(17)-(17)
Stock-based compensation--11---11
Restricted shares to be issued as compensation towards directors---50--50
Issuance of detachable warrants through private placement transactions (Note 3F and Note 3H)--2,567---2,567
Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J)293,59011,742---1,743
Balance as of September 30, 20245,772,026$6$118,223$100$5$(122,356)$(4,022)
(*)Represents amount lower than $1.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.